Castle Biosciences has received official approval from the New York State Department of Health for its IDgenetix atopic dermatitis test. This regulatory green light is critical, as New York often serves as a gatekeeper for specialized diagnostic testing adoption in the broader Northeast market.

The company has been working to scale its dermatology business, though financial results remain pressured. With trailing revenue of $344.2 million and a current net margin of -7.0%, the firm is in a high-spend phase focused on market penetration and test adoption rather than immediate profitability.

The approval creates a binary setup regarding the speed of revenue recognition from the NY region. Investors are now watching to see if this expanded coverage can accelerate top-line growth enough to offset the current burn rate and improve EPS, which stands at -$0.83.